Dear Editor

I read with interest the review from Hellweg \[[@B1]\]. However the findings of Ntoumenopoulos et al. \[[@B2]\] were in-accurately reported.

Ntoumenopoulos et al. \[[@B2]\] investigated the effect of chest physiotherapy in sixty adult patients intubated and mechanically ventilated for at least 48-hours. There were no differences in the duration of mechanical ventilation, length of stay in ICU or mortality. Ventilator-associated pneumonia (VAP) as assessed by combined clinical assessment and the clinical pulmonary infection score (CPIS) occurred in 39% of the control group and 8% of the intervention group (*P* = 0.02). After adjustment was made by logistic regression for other important variables, chest physiotherapy was independently associated with a reduced occurrence of VAP (*P* = 0.02). Therefore, contrary to the conclusions by Hellwegg \[[@B1]\] the work of Ntoumenopoulos et al. \[[@B2]\] provides preliminary evidence that chest physiotherapy in ventilated patients was independently associated with a reduction in VAP.

A randomised controlled trial by Pattanshetty and Gaude \[[@B3]\] reported that twice-daily chest physiotherapy was associated with a significant decrease in the clinical pulmonary infection scores (surrogate measure of VAP) and with a significant reduction in mortality. Blot et al. \[[@B4]\] therefore recommend the further investigation of chest physiotherapy for the prevention of VAP.
